华西医学

华西医学

急性髓系白血病伴t(8;21)的临床特点及预后

查看全文

【摘要】 目的 探讨t(8;21)急性髓系白血病(acute myeloid leukemia,AML)的临床特点及预后,提高对t(8;21)AML的认识。 方法 2010年5月收治1例t(8;21)AML患者,对其临床资料并复习相关文献进行分析。患者因乏力、皮下瘀斑入院,查体发现患者有胸骨压痛,脾肋下3 cm触及,血常规:白细胞80.37×109/L,异常细胞 23%,取患者骨髓液行形态学、流式细胞术检测及染色体核型检测。 结果 患者诊断为急性粒细胞白血病部分分化型(AML-M2b),AML1/ETO融合基因阳性,染色体核型分析t(8;21)(q22;q22)。 结论 t(8;21)AML是一类较为特殊的急性髓系白血病,在诊断时需寻找疾病的预后因素并进行分层,实施个体化治疗。
【Abstract】 Objective To obsrve the clinical features and prognosis of acute myeloid leukemia (AML) with t(8;21). Methods The clinical data of one patient with t (8; 21) AML diagnosed in May 2010 was retrospectively analyzed. The chief complaints of the patient were malaise and ecchymosis. The physical examinations revealed sternum pain and splenomegaly; blood routine examination showed that the peripheral WBC count was 80.37×109/L, and the abnormal cells were 23%. Bone marrow samples were collected to perform the morphologic test, flow cytometry analysis and chromosome analysis. Results The patient was diagnosed as AML with maturation (AML-M2) with positive AML1/ETO fusion gene and translocation (8; 21) (q22; q22). Conclusion AML with t (8; 21) is different with other types of AML; patients with AML with t (8; 21) need individualized treatment.

关键词: 急性髓系白血病; 染色体畸变; 预后

引用本文: 曾帆,刘云,周鹏,谢雪,常红. 急性髓系白血病伴t(8;21)的临床特点及预后. 华西医学, 2010, 25(11): 2004-2006. doi: 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
1.  Prebet T, Boissel N, Reutenauer S, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup[J]. J Clin Oncol, 2009, 27(28): 4747-4753.
2.  Groupe Français de Cytogénétique Hématologique. Acute myelogenous leukemia with an 8;21 translocation: a report on 148 cases from the Groupe Francais de Cytogénétique Hématologique[J]. Cancer Genet Cytogenet, 1990, 44(2): 169-179.
3.  Han JS, Kim SH, Kwon HC, et al. A case of pathologic splenic rupture as the initial manifestation of acute myeloid leukemia M2[J]. Yonsei Med J, 2010. 51(1): 138-140.
4.  Ferrara F, Vecchio. Acute myeloid leukemia with t(8;21)/AML1/ETO: a distinct biological and clinical entity[J]. Haematologica, 2002, 87(3): 306-319.
5.  牧启田, 陈志妹, 楼基余, 等. 154例t(8; 21)急性髓系白血病遗传学分析[J]. 浙江大学学报(医学版), 2010, 39(3): 236-240.
6.  Yamasaki H, Era T, Asou N, et al. High degree of myeloid differentiation and granulocytosis is associated with t(8;21) smoldering leukemia[J]. Leukemia, 1995, 9(7): 1147-1153.
7.  Bae SY, Kim JS, Ryeu BJ, et al. Acute myeloid leukemia (AML-M2) associated with variant t(8;21): report of three cases[J]. Cancer Genet Cytogenet, 2010, 199(1): 31-37.
8.  Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting[J]. Clin Oncol, 1999, 17(12): 3835-3849.
9.  Fleishma E, Sokova O, Popa AV, et al. Chromosomal translocation t(8, 21) in acute myeloid leukemia of children: prognostic value of additional karyotype abnormalities[J]. Vestn Ross Akad Med Nauk, 2009, 19(6): 9-16.
10.  张建军, 杜欣, 黄志新, 等. AM L-1 /ETO 基因相关的AM L-M 2 型白血病免疫表型分析[J]. 中国实验血液学杂志, 2007, 15(2): 378-381.
11.  Felicetto F, Rosa N, Mario A, et al. Immunophenotypic analysis enables the correct prediction of t (8; 21) in acute myeloid leukemia[J]. Br J Haematol, 1998, 102(2): 444-448.
12.  MacDonald AP, Janossy G, Ivo ry K, et al. Leukemia associated changes identified by quantitative flow cytometry CD34 over expression in acute myelogenous leukem ia M2 with t(8; 21)[J]. Blood. 1996, 87(4): 1162-68.
13.  Dunne J, Gascoyne DM, Lister TA, et al. AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia[J]. Cancer Res, 2010, 70(10): 3985-3995.
14.  Wang HW, Yang W, Shao H, et al. Complex t(2;21;8)(p12;q22;q22): a variant t(8;21) in a patient with acute myeloid leukemia (AML-M2) [J]. Cancer Genet Cytogenet 2009, 188(2): 95-98.
15.  Nguyen S, Leblanc T, Fenaux P, et al. A white blood cell index as the mainprognostic factor in t (8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup[J]. Blood, 2002, 99(10): 3517-3523.
16.  方艳红, 刘红星, 童春容, 等. 89例成人融合基因Aml1 / Eto阳性急性髓系白血病长期生存分析[J]. 中国实验血液学杂志, 2009, 17(3): 750-755.
17.  Gorin NC, Labopin, Frassoni F, et al. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t (8;21): a retrospective study from the European Cooperative Group for blood and marrow transplantation[J]. J Clin Oncol, 2008, 26(19): 3183-3188.
18.  Leblanc T, Berger R. Molecular cytogenetics of childhood acute myelogenous leukaemias[J]. Eur J Haematol, 1997, 599(1): 1-13.
19.  Schlenk RF, Benner A, Krauter J, et al. Individual patient data based meta-analysis of patients aged 16 to 60 years with core binding factor acutemyeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup[J]. J Clin Oncol, 2004, 22(3): 3741-3750.
20.  贡金英, 刘旭平, 李承文, 等. 两例急性髓系白血病伴t(6;21;8)(p22;q22;q22) 复杂易位患者的临床与实验室研究[J]. 中华血液学杂志, 2006, 27(5): 314-317.
21.  Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered[J]. J Clin Oncol. 1999, 17(12): 3767-3775.
22.  Maria, Stewart CC, Lawrence D, et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22)[J]. Blood, 1997, 90(4): 1643-1648.
23.  Tawee Tanvetyanon, Sucha Nand, Amir A, et al. Allogeneic transplantation for acute myeloid leukemia (AML) M2 with translocation (8;21) and CD56 positivity is effective even for patients with relapsed disease[J]. Blood, 2004, 104: Abstract 5187.
24.  石红霞, 江滨, 陆道培, 等. 成人t (8; 21)急性髓系白血病M2 型治疗方案及预后分析[J]. 中华血液学杂志, 2005, 26(8): 481-484.